Moderna hired Lonza to make its COVID-19 vaccine in May. Initially, the CDMO will manufacture the vaccine active ingredient—an mRNA molecule in lipid nanoparticles—at plants in the United States and Switzerland.
However, the firms plan to establish additional production suites across Lonza’s worldwide facilities. The aim is to make up to one billion doses of mRNA-1273 per year, assuming a dose of 50 µg.
Preliminary manufacturing work has begun in the United States, according to Lonza spokeswoman, Sanna Fowler.